Is Daiichi Sankyo Gearing Up For Arbitration Against Former Ranbaxy Owners?
This article was originally published in PharmAsia News
Daiichi Sankyo continues to believe previous Ranbaxy shareholders concealed information related to U.S. FDA negotiations. Sources say arbitration in Singapore could be taking shape.
You may also be interested in...
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.